Forteo ® (teriparatide [rDNA origin] injection)

20-mcg daily dose in a 2.4-mL prefilled delivery device

The below information is provided in response to your request and may contain information about doses, uses, formulations and populations different from product labeling. See Prescribing Information above.

Monitoring of Labs with FORTEO® (teriparatide [rDNA origin] injection) Treatment

The Forteo label does not specify labs to monitor; however, available literature offers suggestions on clinical work up prior to, and during therapy.

Clinical work up prior to initiating teriparatide therapy

Clinical tests that may be conducted prior to initiating therapy with Forteo® (teriparatide [rDNA origin] injection) include (Miller, 2004)

  • Lumbar spine and hip bone mineral density (BMD) by dual energy x-ray absorptiometry (DXA)

  • Total serum calcium

  • Total serum alkaline phosphatase

  • 25-hydroxyvitamin D

  • Parathyroid Hormone

  • Creatinine clearance

Follow up tests to teriparatide therapy

Follow up tests to teriparatide therapy that may be utilized include (Miller 2004)

  • Total serum calcium

    • If symptoms such as nausea, vomiting, constipation, lower energy, or muscle weakness arise, as these may be signs of high blood calcium

  • Lumbar spine and hip BMD by DXA after 24 months of therapy

Enclosed Prescribing Information

FORTEO® (teriparatide [rDNA origin] injection), Lilly

The published references below are available upon request by contacting 1-800-LillyRx.

References

Miller PD, Bilezikian JP, Deal C, et al. Clinical use of teriparatide in the real world: initial insights. Endocr Pract. 2004 Mar-Apr;10(2):139-148

Date of Last Review: February 12, 2017

Contact Lilly

Call Us

If you need information about a Lilly product or want to report an Adverse Event or Product Complaint, you may call us.

Available Mon - Fri, 9am - 8pm ET

Or you can

Ask us a question Chat with us

Submit a question

Visit Us @LillyMedical